Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

SGYP 3.44 -0.14 (-3.91%)
price chart
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to ...
Related articles »  
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
Synergy Pharmaceuticals, Inc. ( SGYP ) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior ...
NEW YORK, Oct 28, 2014 (BUSINESS WIRE) -- Synergy Pharmaceuticals Inc. SGYP, +4.68% (the �Company�),a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal ...
Related articles »  
Morning Buzz: iBio (IBIO), Neonode, Inc. (NEON), Synergy Pharmaceuticals ...
Synergy Pharmaceuticals, Inc. (SGYP) are up nearly 8% to $2.95 in early trade in response to a press release from the company that said its Phase 2b study for Plecanatide in patients with irritable bowel syndrome with constipation was positive.
Synergy Pharma presents plecanatide IBS-C clinical trial results
At the American College of Gastroenterology Annual Scientific Meeting, Synergy Pharmaceuticals (SGYP +6.6%) presented data from a 423-patient Phase 2b dose-ranging study assessing the safety and efficacy of plecanatide in patients with irritable bowel ...
Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for ...  PipelineReview.com (press release)
Related articles »  
Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC).
Related articles »  
Major Declarations Stocks: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) data presented at ACG showed that plecanatide, once-daily oral tablet, significantly better complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction as well as significantly ...
Momentum Stocks in Focus- E Commerce China Dangdang, (NYSE:DANG ...  Techsonian (press release)
Related articles »  
Traders Watch list -Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pixelworks ...
Las Vegas, NV �October15, 2014� (TechSonian) �Synergy Pharmaceuticals Inc(NASDAQ:SGYP)declared that it will present additional positive data from a phase 2b study assessing plecanatide's efficacy and safety in patients with irritable bowel syndrome ...